Starpharma Holdings Limited (ASX:SPL)

Market Cap	345.86M +512.6%
Revenue (ttm)	14.58M +250.6%
Net Income	-3.23M
EPS	-0.01
Shares Out	477.05M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,824,632
Open	0.7200
Previous Close	0.7150
Day's Range	0.7100 - 0.7400
52-Week Range	0.1100 - 0.8150
Beta	0.76
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About Starpharma Holdings

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company’s products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom coating. It also involved in the development of a dendrimer-enhance...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 40
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: SPL

Financial Performance

In fiscal year 2025, Starpharma Holdings's revenue was 5.85 million, a decrease of -40.04% compared to the previous year's 9.76 million. Losses were -9.99 million, 22.4% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 19, 2026

Data Sources Report a data error